Researchers are the first to create sensory interneurons from stem cells
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have, for the first time, coaxed human stem cells to become sensory interneurons — the cells that give us our sense of touch. The new protocol could be a step toward stem cell–based therapies to restore sensation in paralyzed people who have lost feeling in parts of their body.
The study, which was led by Samantha Butler, a UCLA associate professor of neurobiology and member of the Broad Stem Cell Research Center, was published today in the journal Stem Cell Reports.
Sensory interneurons, a class of neurons in the spinal cord, are responsible for relaying information from throughout the body to the central nervous system, which enables the sense of touch. The lack of a sense of touch greatly affects people who are paralyzed. For example, they often cannot feel the touch of another person, and the inability to feel pain leaves them susceptible to burns from inadvertent contact with a hot surface.
“The field has for a long time focused on making people walk again,” said Butler, the study’s senior author. “‘Making people feel again doesn’t have quite the same ring. But to walk, you need to be able to feel and to sense your body in space; the two processes really go hand in glove.”
In a separate study, published in September by the journal eLife, Butler and her colleagues discovered how signals from a family of proteins called bone morphogenetic proteins, or BMPs, influence the development of sensory interneurons in chicken embryos. The Stem Cell Reports research applies those findings to human stem cells in the lab.
When the researchers added a specific bone morphogenetic protein called BMP4, as well as another signaling molecule called retinoic acid, to human embryonic stem cells, they got a mixture of two types of sensory interneurons. DI1 sensory interneurons give people proprioception — a sense of where their body is in space — and dI3 sensory interneurons enable them to feel a sense of pressure.
The researchers found the identical mixture of sensory interneurons developed when they added the same signaling molecules to induced pluripotent stem cells, which are produced by reprogramming a patient’s own mature cells such as skin cells. This reprogramming method creates stem cells that can create any cell type while also maintaining the genetic code of the person they originated from. The ability to create sensory interneurons with a patient’s own reprogrammed cells holds significant potential for the creation of a cell-based treatment that restores the sense of touch without immune suppression.
Butler hopes to be able to create one type of interneuron at a time, which would make it easier to define the separate roles of each cell type and allow scientists to start the process of using these cells in clinical applications for people who are paralyzed. However, her research group has not yet identified how to make stem cells yield entirely dI1 or entirely dI3 cells — perhaps because another signaling pathway is involved, she said.
The researchers also have yet to determine the specific recipe of growth factors that would coax stem cells to create other types of sensory interneurons.
The group is currently implanting the new dI1 and dI3 sensory interneurons into the spinal cords of mice to understand whether the cells integrate into the nervous system and become fully functional. This is a critical step toward defining the clinical potential of the cells.
“This is a long path,” Butler said. “We haven’t solved how to restore touch but we’ve made a major first step by working out some of these protocols to create sensory interneurons.”
The Latest on: Stem cell–based therapies
via Google News
The Latest on: Stem cell–based therapies
- ElevateBio, Boston Children’s launch startup to test new approach to “off-the-shelf’ cell therapyon August 4, 2022 at 8:39 am
Spun out of a Boston Children’s research lab, the biotech is the first to emerge from a partnership ElevateBio and the hospital struck to create new cell and gene therapy companies.
- Boston researchers want to create ‘off-the-shelf’ cell therapies to fight canceron August 4, 2022 at 8:00 am
It’s been five years since the first cell therapy was approved by the US Food and Drug Administration, and since then, they have been a critical way to treat aggressive blood cancers.But the current ...
- McMaster professor aims to cure Type 1 diabetes with cell-based therapyon August 3, 2022 at 9:50 am
Dr. Harald Stover says scientists are in pre-clinical work and aiming for trials with human patients in about two years if things go well.
- Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesiaon August 1, 2022 at 4:00 am
(“Meso Numismatics” or the “Company”) (MSSV), a technology company specializing in Biotech and Numismatics, is pleased to announce additional global expansion by opening stem cell therapy and ...
- Progress toward a stem cell–based therapy for blindnesson July 29, 2022 at 6:34 am
What if, in people with blinding retinal disorders, one could simply introduce into the retina healthy photoreceptor cells derived in a dish from stem cells, and restore sight?
- Man cured of HIV, cancer following breakthrough stem cell transplant: Doctorson July 28, 2022 at 4:05 pm
A 66-year-old man who was diagnosed with HIV in 1988 is said to be free of both the HIV virus and cancer, following a stem cell transplant from an unrelated donor for leukemia, according to a ...
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With ‘Favorable Survival Outcomes’ in Group of Rare Blood Cancerson July 26, 2022 at 12:00 pm
The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of ...
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends, Share, Industry Size, Growth, Demand, Opportunities and Forecast By 2029on July 22, 2022 at 8:36 am
Autologous Stem Cell and Non-Stem Cell Based Therapies Market business report provides detailed information on important aspects such as drivers and constraints that define the future growth of ...
- Cancer Stem Cells market is projected to grow at 15% CAGR by 2029: DataM Intelligenceon July 13, 2022 at 11:01 am
Others), by Mode of Action (Stem Cell-Based Cancer Therapy, Targeted Cancerous Stem Cells (CSCs), by End User (Hospitals, Specialized Cancer Treatment Centers, Research Institutes, Others): Global ...
via Bing News